KURA
Kura Oncology, Inc.
There isn't enough reported data to score KURA yet.
KURA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
KURA's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
KURA PE Valuation
KURA has no meaningful PE right now: it lost money over the past year.
KURA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect KURA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
KURA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.30 | -$0.83 |
| Q2 2026 | -$3.37 | -$1.12 |
| Q1 2026 | -$3.35 | -$1.26 |
| Q4 2025 | -$3.18 | -$1.16 |
| Q3 2025 | -$2.47 | -$0.11 |
| Q2 2025 | -$2.25 | -$0.02 |
| Q1 2025 | -$2.09 | +$0.08 |
| Q4 2024 | -$2.02 | +$0.06 |
KURA lost $3.30 per share over the past year, a bigger loss than the year before.
KURA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22.8M | +10% |
| Q2 2026 | $20.9M | +37% |
| Q1 2026 | $18.3M | +29% |
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -327% | +59 points |
| Q2 2026 | -350% | +126 points |
| Q1 2026 | -432% | +27 points |
| Q4 2025 | -498% | N/A |
| Q3 2025 | -386% | N/A |
| Q2 2025 | -475% | N/A |
| Q1 2025 | -459% | N/A |
KURA's operating margin was −327% last quarter, up 59 points from the same quarter a year ago.
KURA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$54.9M | +$28.3M |
| Q2 2026 | -$63.2M | -$33M |
| Q1 2026 | -$86M | -$13.8M |
| Q4 2025 | $115M | -57% |
| Q3 2025 | -$83.2M | -$39.8M |
| Q2 2025 | -$30.2M | +$12.3M |
| Q1 2025 | -$72.2M | -$23.3M |
| Q4 2024 | $268.8M | +$303.1M |
KURA has burned cash in almost every quarter: −$89M over the past year, against $83M the year before.
KURA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +962K shares |
| 1 year | +2.5% | +2.2M shares |
| 3 years | +16% | +12.6M shares |
| 5 years | +35% | +23.5M shares |
| Available history | +98% | +44.5M shares |
KURA has 90M diluted shares, up 2.5% from a year ago.
KURA Net Leverage
KURA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
KURA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.4 | Neutral |
| Stochastic | 15.0 | Oversold |
KURA's weekly RSI is 38 (neutral) and its Stochastic is 15 (oversold).
KURA PE vs Healthcare Sector
KURA has no meaningful PE right now: it lost money over the past year.
KURA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.46 | 21% below |
| 20 week MA | $10.5 | 29% below |
| 50 week MA | $9.76 | 24% below |
| 100 week MA | $8.72 | 15% below |
| 200 week MA | $11.9 | 37% below |
KURA is in a downtrend: it's below all five of its weekly moving averages, and 37% below its 200-week average.
KURA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.2 | $36.0 | +153% |
| 2021 | $36.0 | $16.1 | -55% |
| 2022 | $16.1 | $11.7 | -27% |
| 2023 | $11.7 | $14.4 | +23% |
| 2024 | $14.4 | $8.67 | -40% |
| 2025 | $8.67 | $10.6 | +23% |
| 2026 YTD | $10.6 | $7.43 | -30% |
KURA's yearly returns have swung widely, from +153% in 2020 to −55% in 2021. It's down 30% so far in 2026.